A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients With Newly-Diagnosed Glioblastoma Multiforme.
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs AT 101 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Oct 2009 Primary endpoint 'Maximum tolerated dose' has been met.
- 26 Oct 2009 Results were presented in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology and AANS/CNS Section on Tumors (Concurrent Session VI: Radiation Oncology, October 23; Abstract 449), according to an Ascenta media release.